Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Akebia Therapeutics (AKBA) Receivables - Net (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Receivables - Net for 9 consecutive years, with $47.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 36.85% to $47.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $47.0 million, a 36.85% increase, with the full-year FY2025 number at $47.0 million, up 36.85% from a year prior.
  • Receivables - Net was $47.0 million for Q4 2025 at Akebia Therapeutics, down from $66.2 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $81.9 million in Q2 2022 to a low of $17.8 million in Q1 2023.
  • A 5-year average of $42.6 million and a median of $37.3 million in 2021 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: skyrocketed 7268.71% in 2021, then plummeted 76.09% in 2023.
  • Akebia Therapeutics' Receivables - Net stood at $51.6 million in 2021, then fell by 21.9% to $40.3 million in 2022, then decreased by 2.47% to $39.3 million in 2023, then dropped by 12.53% to $34.4 million in 2024, then surged by 36.85% to $47.0 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Receivables - Net are $47.0 million (Q4 2025), $66.2 million (Q3 2025), and $72.8 million (Q2 2025).